FORMULATION ARTICLES

FORMULATION VIDEOS

There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.

Explore how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

Achieving cost-effective manufacturing while maintaining high quality standards today is one of the biggest challenges facing companies outsourcing mRNA/RNA development. In turn, panelists Qian Ruan, Andy Geall, and Alex Aust reflect on how and where they’ve seen the costs of mRNA-LNP manufacturing evolving/fluctuating in recent years.

Discover how continuous manufacturing of nanoparticles can improve process efficiency, reduce costs, and increase the quality of the final drug product.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS